Behavioral Health

Perinatal mood and anxiety disorders: screening and care

Clinical Overview and When to Suspect Perinatal Mood and Anxiety Disorders

— Affect ~1 in 5 perinatal patients; leading cause of pregnancy-related mortality in the US when suicide and overdose are included.

— Often underdiagnosed: symptoms attributed to "normal" pregnancy/postpartum fatigue, sleep loss, or hormonal shifts.

— Persistent low mood, anhedonia, tearfulness, or irritability >2 weeks

— Excessive worry about fetal/infant health that impairs function

— Intrusive thoughts of harm to baby (OCD spectrum) vs. command hallucinations (psychosis)

— Poor maternal-infant bonding, missed prenatal/pediatric visits, weight changes outside expected ranges

— Somatic complaints without clear medical cause (headaches, palpitations, GI)

— Prior depression/anxiety (strongest predictor; recurrence risk ~30–50%)

— Prior PMAD, bipolar disorder (postpartum psychosis risk up to 25–50%)

— Intimate partner violence, low social support, unintended pregnancy

— Recent pregnancy loss, NICU admission, traumatic birth

— Adolescents, low income, racial/ethnic minorities (disparities in screening and treatment access)

— Postpartum blues: onset days 2–5, resolves by day 14, no functional impairment

— Postpartum depression (PPD): onset within 12 months, ≥2 weeks of symptoms

— Postpartum psychosis: emergent, typically within first 2 weeks; psychiatric emergency

Board pearl: ACOG and USPSTF both recommend universal screening for depression and anxiety at least once during pregnancy and again postpartum, with many practices screening at the initial OB visit, third trimester, and 6-week postpartum visit, plus well-child visits through 12 months. A negative screen earlier does not exclude later onset—rescreen.

Perinatal mood and anxiety disorders (PMADs) encompass depression, anxiety, OCD, PTSD, bipolar disorder, and psychosis arising during pregnancy or within 12 months postpartum.

When to suspect in any prenatal or postpartum visit:

High-risk profiles:

Time course distinctions:

Presentation Patterns and Key History

— SIGECAPS criteria same as MDD, but contextualized: sleep disturbance beyond infant feeding, guilt about mothering, anhedonia toward baby

— Onset typically within 4–6 weeks postpartum but DSM-5 "peripartum onset" specifier covers pregnancy through 4 weeks; clinically extended to 12 months

— Tearfulness, feelings of inadequacy as a mother, intrusive thoughts of self-harm

— Excessive worry about pregnancy outcomes, infant feeding, SIDS

— Physical: insomnia even when baby sleeps, palpitations, GI upset, muscle tension

— Often co-occurs with depression (~50% overlap)

— Ego-dystonic intrusive thoughts of accidentally or intentionally harming infant (dropping, smothering, contamination)

— Patient is distressed, avoids baby, checks repeatedly — not psychotic, no intent

— Frequently misdiagnosed; reassurance that this is treatable OCD is therapeutic

— Triggered by traumatic delivery, NICU course, prior obstetric loss, sexual trauma history

— Flashbacks, avoidance of pelvic exams, hyperarousal at infant cries

— Rapid onset days 1–14 postpartum

— Waxing/waning confusion, delusions (often about the infant), hallucinations, mood lability

— Strongly associated with bipolar I disorder; high recurrence in subsequent pregnancies

Key distinction: OCD intrusions = ego-dystonic, distressing, no plan → outpatient SSRI + CBT. Psychotic thoughts = ego-syntonic, command hallucinations, delusional belief that harming infant is justified → immediate hospitalization, do not leave parent alone with infant.

— Personal/family psychiatric history, especially bipolar disorder

— Sleep (independent of infant), appetite, suicidal/infanticidal ideation

— Substance use, IPV screening, social support, breastfeeding plans

— Medication history including herbal supplements and prior antidepressant response

Postpartum depression (PPD) — most common PMAD presentation:

Perinatal anxiety/GAD:

Perinatal OCD:

Perinatal PTSD:

Postpartum psychosis — psychiatric emergency:

Key history to gather:

Physical Exam Findings and Mental Status Assessment

— Disheveled grooming, flat affect, poor eye contact, psychomotor slowing or agitation

— Tearfulness during routine questioning; minimal interaction with infant if present

— In psychosis: disorganization, responding to internal stimuli, agitation, perplexity

— Tachycardia, tremor, weight loss → screen for hyperthyroidism (postpartum thyroiditis up to 5–10%)

— Bradycardia, dry skin, delayed reflexes, weight gain → hypothyroidism

— Pallor, fatigue → postpartum anemia (Hgb, ferritin)

— Fever, uterine tenderness → endometritis or sepsis can mimic agitated depression

— BP elevation → consider preeclampsia/postpartum hypertension contributing to anxiety symptoms

— Mood and affect congruence; sleep history independent of infant care

— Thought content: passive death wishes vs. active suicidal ideation with plan/intent; thoughts of harming infant — characterize as intrusive (OCD) vs. command (psychosis)

— Insight, judgment, cognition (assess orientation in suspected psychosis)

— Always assess infant safety: bonding, feeding, response to cry

— Affect during feeding, eye contact with infant, responsiveness to infant cues

— Concern for neglect prompts pediatric and social work involvement

— Edinburgh Postnatal Depression Scale (EPDS): 10 items, score ≥10 positive; item 10 specifically asks about self-harm

— PHQ-9 acceptable alternative; GAD-7 for anxiety

— Positive screen requires diagnostic interview, not direct treatment based on score alone

Step 3 management: A positive EPDS at the 6-week postpartum visit obligates same-visit safety assessment (SI, infanticidal ideation, psychosis features), brief diagnostic interview, initiation of treatment plan, and documented follow-up within 1–2 weeks — do not simply refer and discharge.

PMADs are clinical diagnoses; physical exam primarily rules out medical mimics and assesses safety/function.

General appearance and behavior:

Vital signs and somatic exam:

Mental status exam essentials:

Maternal-infant dyad observation:

Standardized tools to apply at point of care:

Diagnostic Workup — Initial Labs and Medical Mimics

— TSH ± free T4: postpartum thyroiditis classically biphasic (transient hyperthyroidism at 1–4 months, hypothyroidism at 4–8 months); either phase can mimic anxiety or depression

— CBC: postpartum anemia worsens fatigue and depressive symptoms; treat iron deficiency

— Ferritin: low ferritin independently associated with PPD even without overt anemia

— Comprehensive metabolic panel: electrolytes, glucose, hepatic/renal function (baseline before SSRI)

— Vitamin D, B12 if dietary concerns or symptoms suggest

— Urine toxicology if substance use suspected (with consent and awareness of reporting implications)

— Palpitations/tremor → repeat TSH, consider catecholamines if severe

— Persistent headache, vision changes, hypertension postpartum → evaluate for preeclampsia/PRES, not anxiety

— Confusion or fever postpartum → infectious workup, autoimmune encephalitis (anti-NMDA) in atypical psychosis

— Heavy bleeding, dizziness → CBC, consider Sheehan syndrome (lactation failure + hypotension + adrenal insufficiency)

— EPDS at initial OB, third trimester, and postpartum (typically 4–6 weeks)

— Repeat at well-child visits per AAP through 12 months

— GAD-7 routinely paired with depression screening

— MDQ (Mood Disorder Questionnaire) or careful history of prior hypomania/mania

— Critical: starting an SSRI in undiagnosed bipolar disorder can precipitate mania or postpartum psychosis

Board pearl: A postpartum patient with new-onset anxiety, tremor, palpitations, and weight loss at 2–3 months postpartum should get a TSH before antidepressant initiation — postpartum thyroiditis presents this way and is missed if you anchor on PPD. Conversely, a fatigued, cold-intolerant patient at 5 months postpartum may have hypothyroid phase mimicking depression.

PMADs are diagnosed clinically using DSM-5 criteria with peripartum-onset specifier; labs are obtained to exclude organic contributors, not confirm diagnosis.

Recommended initial labs in new or atypical presentations:

Targeted testing based on symptoms:

Screening instruments as documentation:

Bipolar screen before SSRI:

Diagnostic Workup — Advanced Evaluation and Risk Tools

— Neuroimaging (MRI brain) to rule out PRES, cerebral venous sinus thrombosis (postpartum prothrombotic state), pituitary apoplexy/Sheehan

— LP if meningoencephalitis suspected

— Anti-NMDA receptor antibody testing if psychosis with autonomic instability, seizures, or movement disorder — paraneoplastic ovarian teratoma is classic association

— EEG for atypical encephalopathy

— Reassess diagnosis (bipolar, PTSD, substance use)

— Therapeutic drug monitoring if adherence unclear

— Pharmacogenomic testing not routinely recommended but considered in repeated failures

— Sleep study if obstructive sleep apnea suspected (postpartum weight, snoring)

— Columbia Suicide Severity Rating Scale (C-SSRS) is standard

— Stratify into low/moderate/high based on ideation type, intent, plan, access to means, prior attempts

— Document risk and protective factors, safety plan, lethal means counseling (firearm storage — leading method in maternal suicide)

— Direct questions: "Have you had thoughts of harming your baby?" — distinguish intrusive vs. command/delusional

— If concerning, assess access to infant, supervision, support persons

— Consider Child Protective Services consultation only when neglect or imminent danger is identified

— Postpartum Bonding Questionnaire when indicated

— Pediatric well-child visit reports of feeding, weight gain, attachment

Step 3 management: In a postpartum patient with rapid-onset confusion, paranoia about her infant, and insomnia at day 7 postpartum, the first step is hospitalization with psychiatry and OB co-management, not outpatient SSRI. Workup proceeds inpatient: TSH, CBC, BMP, urine tox, neuroimaging, and consideration of autoimmune encephalitis if features warrant.

Most PMADs require no advanced testing; advanced workup is reserved for atypical features, psychosis, treatment resistance, or safety concerns.

For suspected postpartum psychosis or acute confusion:

For treatment-resistant depression:

Suicide risk stratification:

Infant safety assessment:

Functional and bonding assessment:

Risk Stratification and First-Line Management Logic

— Psychotherapy first-line: CBT or interpersonal therapy (IPT)

— Peer support groups, lactation support, sleep hygiene, exercise

— Reassess in 2 weeks; escalate to medication if no improvement

— Combined pharmacotherapy + psychotherapy is superior to either alone

— SSRI initiation with shared decision-making about breastfeeding

— Weekly to biweekly follow-up until stable

— Psychiatric hospitalization or intensive outpatient/partial program

— Pharmacotherapy with consideration of brexanolone or zuranolone (rapid-acting neurosteroids approved for PPD)

— ECT for severe, psychotic, or refractory depression — safe in pregnancy and lactation

— Immediate hospitalization

— Antipsychotic + mood stabilizer (lithium often used); ECT highly effective

— Do not leave patient alone with infant

— Negative screen: routine rescreening at next interval

— Positive screen without safety concern: diagnostic interview, initiate treatment or referral, follow-up ≤2 weeks

— Positive screen with SI/infanticidal ideation/psychosis: same-day psychiatric evaluation, do not discharge without safety plan

— Positive screen with bipolar features: refer to psychiatry before starting SSRI

— Discuss risks of untreated illness (preterm birth, low birth weight, impaired bonding, suicide) vs. medication risks

— Untreated maternal depression has measurable effects on infant cognitive and emotional development

Board pearl: Untreated perinatal depression is not the safe choice. The exam-correct framing is that untreated maternal depression carries clear maternal and infant risks; medication decisions weigh treatment risk against the risk of doing nothing.

Treatment intensity is matched to severity, functional impairment, safety risk, and breastfeeding preferences.

Mild symptoms (EPDS 10–12, no SI, preserved function):

Moderate symptoms (EPDS 13–19, functional impairment, no acute safety issue):

Severe symptoms (EPDS ≥20, SI, psychosis, inability to care for self/infant):

Postpartum psychosis — always severe:

Screening result → action algorithm:

Shared decision-making framework:

Pharmacotherapy — First-Line Regimens

— Sertraline: first-line in lactation due to low milk transfer and minimal infant serum levels; also widely used in pregnancy

— Escitalopram: good efficacy/tolerability; acceptable in pregnancy and lactation

— Fluoxetine: long half-life and higher milk levels — generally avoided as first choice in lactation but acceptable if previously effective

— Paroxetine: historically associated with cardiac malformations (Ebstein-like, septal defects) in first trimester — avoid in pregnancy when possible; acceptable in lactation

— Citalopram: QT concerns at higher doses

— Start low (sertraline 25–50 mg/day, escitalopram 5–10 mg/day), titrate every 1–2 weeks

— Full effect in 4–6 weeks; partial response should be reassessed at 2–4 weeks

— Continue effective dose at least 6–12 months after remission

— Reasonable second-line; venlafaxine has hypertension risk

— Useful when comorbid pain or prior response

— Useful adjunct; lower libido side effects; avoid in eating disorders/seizure risk

— Lactation-compatible

— Short-term use only for severe anxiety/insomnia bridging SSRI onset

— Risk of neonatal sedation, withdrawal, accidental infant injury due to maternal sedation

— Brexanolone IV 60-hour infusion, inpatient, REMS program

— Zuranolone oral, 14-day course, rapid onset — newer option

— Both for moderate-to-severe PPD; do not replace standard maintenance therapy

— SSRIs in late pregnancy: neonatal adaptation syndrome (jitteriness, feeding issues, transient) and small absolute increase in PPHN risk — do not abruptly discontinue

— Discontinuation in pregnancy is associated with ~70% relapse in women with recurrent depression

Step 3 management: A postpartum patient breastfeeding with new moderate depression — start sertraline 50 mg daily, titrate to 100–150 mg, continue breastfeeding, refer for CBT/IPT, follow up in 2 weeks. Do not advise weaning solely to permit SSRI use.

SSRIs are first-line for perinatal depression and anxiety in both pregnancy and lactation.

Preferred agents:

Dosing and titration:

SNRIs (venlafaxine, duloxetine):

Bupropion:

Benzodiazepines:

Neurosteroid GABA-A modulators (PPD-specific):

Pregnancy-specific counseling:

Expanded Pharmacology — Bipolar, Psychosis, and Special Scenarios

— Highest-risk window for postpartum psychosis and mood episodes

— Lithium: small absolute risk of Ebstein anomaly (~1/1000–2000), historically overstated; often continued in pregnancy with fetal echo at 18–20 weeks and dose adjustments

— Valproate: contraindicated in pregnancy — neural tube defects, cognitive impairment, ~10% major malformation rate

— Carbamazepine: also teratogenic; avoid

— Lamotrigine: preferred mood stabilizer in pregnancy for bipolar depression; dose adjustments needed due to changing pregnancy pharmacokinetics

— Lactation: lithium possible with infant monitoring (levels, TSH, BUN); lamotrigine and valproate generally compatible

— Quetiapine, olanzapine, risperidone, aripiprazole used in perinatal bipolar and psychosis

— Monitor for gestational diabetes (olanzapine, quetiapine higher risk)

— Haloperidol acceptable; clozapine generally avoided in lactation (agranulocytosis risk in infant)

— Inpatient stabilization with antipsychotic + mood stabilizer (lithium gold standard)

— ECT highly effective and rapid — strongly consider for severe, suicidal, infanticidal, or catatonic presentations

— Plan prophylaxis in future pregnancies (often lithium reintroduction immediately postpartum)

— SSRIs at standard or higher doses; CBT/exposure therapy

— Prazosin for nightmares (limited perinatal data; case-by-case)

— Opioid use disorder: methadone or buprenorphine maintenance — both compatible with pregnancy and breastfeeding; neonatal abstinence syndrome managed pediatric side

— Alcohol use disorder: naltrexone preferred postpartum; avoid disulfiram in pregnancy

— SSRI + triptan/tramadol/linezolid → serotonin syndrome risk

— Lithium: monitor levels every trimester and 24h postpartum (volume shifts), TSH, renal function

— Lamotrigine levels drop ~50% in pregnancy — uptitrate, then reduce postpartum to avoid toxicity/rash

Board pearl: A patient with bipolar I on valproate planning pregnancy → transition to lamotrigine or lithium preconception with folate supplementation; never abruptly stop a mood stabilizer in a stable bipolar patient — relapse risk approaches 80–100% in pregnancy.

Bipolar disorder in pregnancy/postpartum:

Antipsychotics:

Postpartum psychosis treatment:

PTSD and OCD:

Substance use comorbidity:

Drug interactions and monitoring:

Special Populations — Medical Comorbidities and Organ Dysfunction

— Most SSRIs are hepatically metabolized; reduce doses or extend intervals

— Sertraline and escitalopram have favorable profiles; avoid duloxetine in significant hepatic disease

— Monitor LFTs at baseline and periodically if abnormalities

— Lithium is renally cleared — contraindicated or requires extreme caution in CKD; check baseline GFR and monitor every 3–6 months

— Gabapentin (sometimes used for anxiety/sleep) requires renal dose adjustment

— SSRIs generally safe but watch for SIADH/hyponatremia, especially in older patients or those on diuretics

— Citalopram >40 mg and escitalopram at higher doses → QT prolongation; obtain ECG if structural heart disease, electrolyte issues, or concurrent QT-prolonging drugs

— TCAs: avoid in cardiac disease (conduction effects, overdose lethality)

— Venlafaxine can raise BP — monitor in hypertensive patients

— Higher rates of obstetric complications that precipitate or worsen PMADs (preeclampsia, gestational diabetes, NICU admissions, pregnancy loss)

— Start SSRIs at lower doses; watch for falls, hyponatremia, bone density effects with prolonged use

— Antipsychotics (olanzapine, quetiapine) worsen weight gain and insulin resistance

— Screen for gestational diabetes earlier; consider aripiprazole or lurasidone alternatives

— Bupropion lowers seizure threshold — avoid

— Coordinate with neurology on antiepileptic choice (avoid valproate in women of reproductive age generally)

— Postpartum thyroiditis common; comorbid hypothyroidism worsens depression — replace levothyroxine to TSH goal before declaring antidepressant failure

Key distinction: When evaluating an older postpartum patient with depression on citalopram + furosemide + tramadol, three risks converge: QT prolongation, hyponatremia, and serotonin syndrome. Step 3 favors switching to sertraline, replacing tramadol with non-serotonergic analgesia, and checking sodium and ECG before titrating.

Hepatic impairment:

Renal impairment:

Cardiac comorbidities:

Older perinatal patients (advanced maternal age, ≥35):

Obesity and metabolic disease:

Seizure disorders:

Thyroid disease:

Special Populations — Adolescents, Loss, NICU, and Cultural Considerations

— Higher PMAD prevalence (up to 50%); often co-occurring trauma, IPV, food insecurity

— Confidentiality nuances vary by state — know your state's minor consent for mental health and contraception

— SSRIs in adolescents carry black box warning for suicidality — does not contraindicate use, but mandates close monitoring (weekly initially, then biweekly)

— Engage school, family, pediatric care; consider home visiting programs

— Up to 30–50% develop depression, PTSD, or complicated grief

— Distinguish normal grief (waves, preserved self-worth) from major depression (persistent worthlessness, anhedonia, SI)

— Avoid platitudes; offer bereavement resources, memory-making, follow-up at 2 and 6 weeks

— Do not rush pharmacotherapy in uncomplicated grief, but treat depression if criteria met

— Up to 40% experience clinically significant depression, anxiety, or PTSD

— Integrate mental health screening into NICU social work; transition planning at discharge is high-risk window

— Cumulative emotional burden; screen during and after treatment cycles regardless of outcome

— Increased PMAD risk related to minority stress, fewer support resources, discrimination in care settings

— Use affirming language, partner inclusion, screening with both birthing and non-birthing parent

— Validated EPDS translations in many languages — use them; interpreter required when needed

— Stigma around mental illness varies; somatic presentations more common in some cultures

— Engage community health workers, doulas, faith-based resources

— Paternal/partner postpartum depression occurs in ~10%; screen partners, particularly when birthing parent is affected

Step 3 management: After a 20-week stillbirth, schedule a follow-up visit at 2 weeks for grief assessment, EPDS screening, contraception counseling, and discussion of future pregnancy planning — do not wait for the routine 6-week postpartum visit.

Pregnant and parenting adolescents:

Perinatal loss (miscarriage, stillbirth, neonatal death, TOP):

NICU parents:

Infertility and ART:

LGBTQ+ perinatal patients:

Cultural and language considerations:

Partners and non-birthing parents:

Complications and Adverse Outcomes

— Suicide: a leading cause of pregnancy-related maternal death in the US; risk peaks postpartum, often by violent means (firearms)

— Substance use: self-medication with alcohol, opioids, benzodiazepines

— Poor adherence to prenatal care, missed appointments, inadequate nutrition

— Worsened medical comorbidities (poorly controlled diabetes, hypertension)

— Preterm birth, low birth weight, small for gestational age

— Preeclampsia (associations reported)

— Reduced breastfeeding initiation and duration

— Impaired maternal-infant bonding

— Failure to thrive, attachment disturbances

— Cognitive, language, and emotional development delays demonstrable through school age

— Higher rates of behavioral problems and mental illness in children

— Neonatal adaptation syndrome in 20–30% of late-pregnancy SSRI-exposed infants: jitteriness, irritability, feeding difficulty, transient respiratory issues — typically resolves within 2 weeks, supportive care

— Small absolute risk of persistent pulmonary hypertension of the newborn (PPHN) with late-pregnancy SSRI exposure

— Paroxetine first-trimester cardiac malformations

— Lithium toxicity from postpartum volume shifts; recheck level 24h postpartum and reduce to prepregnancy dose

— Suicide and infanticide: rare but devastating; psychosis carries the highest acute risk among PMADs

— Disorganization leading to neglect

— Abrupt SSRI discontinuation → maternal relapse and discontinuation syndrome

— Telling a breastfeeding patient she must wean to take an SSRI → undermines treatment and bonding

Board pearl: The exam-tested framing: untreated maternal depression has measurable adverse effects on the fetus and infant; SSRI risks are real but smaller in absolute terms than the consequences of untreated illness. Choose treatment, not avoidance.

Maternal complications of untreated PMADs:

Obstetric and neonatal complications of untreated antenatal depression/anxiety:

Infant and child outcomes:

Treatment-related concerns (managed, not avoided):

Postpartum psychosis-specific risks:

Iatrogenic harms to avoid:

When to Escalate Care — Hospitalization, Consults, and Crisis Pathways

— Active suicidal ideation with plan, intent, or means

— Infanticidal ideation that is non-intrusive (command, delusional, or with intent)

— Postpartum psychosis — always admit

— Severe functional impairment: unable to eat, sleep, or care for self/infant

— Catatonia, severe agitation

— Positive screen with safety concerns not meeting admission criteria

— Diagnostic uncertainty (bipolar vs. unipolar, OCD vs. psychosis)

— Treatment-resistant depression

— Need for ECT consideration or brexanolone/zuranolone initiation

— Substance use disorders requiring MAT

— Increasingly the standard for moderate-to-severe perinatal illness

— Telepsychiatry and perinatal psychiatry access programs (e.g., state-based MCPAP-like consultation lines) expand reach

— Mother-baby psychiatric units exist in some centers; most US hospitalizations separate mother and infant

— Coordinate lactation support (pumping supplies) to preserve breastfeeding when desired

— Pediatrics and social work engagement for infant care during admission

— No improvement at 4–6 weeks of adequate SSRI dose → titrate, augment, or switch

— Worsening symptoms at any visit → escalate frequency to weekly, consider higher level of care

— New psychotic, manic, or suicidal features → emergent evaluation

— 988 Suicide and Crisis Lifeline (Maternal Mental Health subline: press 4 or text "HOME" services)

— Postpartum Support International (PSI) helpline

— Local mobile crisis teams

— Confirmed outpatient follow-up within 7 days

— Safety plan, lethal means restriction (firearm storage counseling), medication reconciliation

— Identified support person, infant safety plan

CCS pearl: For a postpartum patient presenting at day 10 with paranoid delusions about her infant — orders include admit to inpatient psychiatry, psychiatry consult STAT, OB consult, pediatrics/social work consult for infant safety, TSH, CBC, BMP, urine tox, head CT, antipsychotic, no medical decision capacity for discharge AMA. Advance the clock only after safety is secured.

Indications for immediate psychiatric hospitalization:

Indications for urgent (same-day) psychiatric consultation:

OB-psychiatry co-management model:

Inpatient logistics:

Outpatient escalation criteria:

Crisis resources to know and document:

Discharge planning from any acute setting:

Key Differentials — Other Psychiatric and Mood Conditions

— Onset days 2–5, resolves by day 14

— Tearfulness, mood lability, mild anxiety; no functional impairment, no SI

— Treatment: reassurance, sleep, support; rescreen at 2 and 6 weeks

— Risk factor for subsequent PPD

— DSM-5 criteria during pregnancy or within 4 weeks postpartum (clinically extended to 12 months)

— ≥2 weeks of symptoms with functional impairment

— Critical to distinguish before SSRI initiation — antidepressants can precipitate mania, mixed states, or rapid cycling

— Screen with MDQ, family history, prior episodes of decreased sleep need with energy/productivity

— Postpartum is highest-risk window for first manic or psychotic episode in predisposed patients

— Rapid onset, days to 2 weeks postpartum

— Delusions (often infant-focused), hallucinations, disorganization, waxing/waning sensorium

— Most cases reflect underlying bipolar disorder

— GAD, panic disorder, illness anxiety, specific phobias (e.g., tokophobia — fear of childbirth)

— Ego-dystonic intrusive thoughts, compulsive checking, distress

— Differentiated from psychosis by insight and absence of intent

— Re-experiencing, avoidance (e.g., refusing pelvic exams), hyperarousal, negative cognitions

— Often missed because symptoms overlap with anxiety/depression

— Symptoms in response to identifiable stressor, not meeting full MDD criteria

— Treat with therapy, supports; medication if persistent

Key distinction: A 30-year-old at day 12 postpartum, not sleeping, talking rapidly about "saving" her baby through a special diet, with delusional intensity → postpartum psychosis with mania, not anxiety. An SSRI alone would be wrong; admit and initiate antipsychotic + mood stabilizer, consider ECT.

Postpartum blues:

Major depressive disorder, peripartum-onset specifier:

Bipolar disorder (I or II):

Postpartum psychosis:

Perinatal anxiety disorders:

Perinatal OCD:

PTSD related to traumatic birth or prior trauma:

Adjustment disorder:

Key Differentials — Medical and Substance-Related Mimics

— Postpartum thyroiditis (5–10% of postpartum patients): hyper phase (anxiety, palpitations, tremor, weight loss) at 1–4 months; hypo phase (fatigue, cold intolerance, weight gain, depression) at 4–8 months; often resolves but may leave permanent hypothyroidism

— Sheehan syndrome: postpartum pituitary infarction after hemorrhage — lactation failure, fatigue, hypotension, hyponatremia, adrenal insufficiency; can mimic depression

— Hyperparathyroidism, Cushing, pheochromocytoma (rare)

— Postpartum anemia (iron deficiency, blood loss)

— Vitamin B12, folate, vitamin D deficiencies

— Severe iron deficiency can cause restless legs and fatigue mimicking depression

— Cerebral venous sinus thrombosis (postpartum prothrombotic state): headache, seizures, focal deficits — not depression

— Posterior reversible encephalopathy syndrome (PRES): postpartum hypertension, headache, visual changes, confusion

— Migraine, sleep deprivation

— Autoimmune encephalitis (anti-NMDA): psychiatric features + autonomic instability, seizures, dyskinesias; check for ovarian teratoma

— Endometritis, mastitis with systemic illness can produce fatigue and low mood

— HIV, syphilis, hepatitis — screen if risk factors

— Alcohol use disorder, opioid use disorder, stimulant use (methamphetamine can mimic psychosis or mania)

— Cannabis use → anxiety, motivation changes

— Withdrawal states (benzodiazepine, opioid) can mimic anxiety/agitated depression

— Prescription contributors: corticosteroids (mood swings, psychosis), interferon, beta-blockers (depression), hormonal contraception (variable)

— Obstructive sleep apnea unmasked by pregnancy weight gain

— Severe sleep deprivation as a mimic — but also a true precipitant of postpartum psychosis in bipolar patients

Step 3 management: Before declaring antidepressant treatment failure in a postpartum patient, recheck TSH, CBC, ferritin, B12, vitamin D, urine toxicology, and review medication list including hormonal contraceptives — addressing thyroid disease or iron deficiency may obviate or augment psychiatric treatment.

Endocrine:

Hematologic and nutritional:

Neurologic:

Infectious:

Substance-related:

Sleep disorders:

Secondary Prevention and Long-Term Plan

— Continue effective antidepressant for at least 6–12 months after remission

— For recurrent depression (≥2 prior episodes) or severe presentations, consider indefinite maintenance

— Do not stop antidepressants for subsequent pregnancies in patients with recurrent illness — relapse risk ~70%

— Pre-pregnancy psychiatric consultation for any patient with history of PMAD, bipolar disorder, or psychosis

— Optimize medication regimens preconception (e.g., switch valproate → lamotrigine; ensure folic acid)

— Plan postpartum prophylaxis: lithium reintroduction immediately postpartum dramatically reduces recurrence of postpartum psychosis in bipolar I

— CBT or IPT for 12–16 sessions during acute treatment; booster sessions as needed

— Group therapy and peer support (PSI, Mom2Mom) for ongoing connection

— Sleep protection (partner-assisted feeding shifts, especially in bipolar/psychosis history)

— Exercise (≥150 min/week moderate activity) — evidence-supported antidepressant effect

— Nutrition, light exposure, social engagement

— Limit alcohol; substance use treatment if applicable

— Critical to allow recovery and planned subsequent pregnancies

— Consider long-acting reversible contraception (LARC); be alert that some patients experience mood changes with hormonal methods

— Discuss interpregnancy interval (≥18 months ideal)

— Family history of bipolar disorder or postpartum psychosis informs prophylaxis planning

— Paid leave, lactation support, home visiting programs (Nurse-Family Partnership), WIC, Medicaid extension postpartum (12 months in many states)

— Address IPV, housing, food security as part of treatment

Board pearl: A patient with prior postpartum psychosis planning another pregnancy → preconception psychiatry referral, plan for lithium prophylaxis initiated immediately postpartum, dedicated sleep protection, and close postpartum monitoring through 6 months reduces recurrence from ~50% toward ~10%.

Continuation and maintenance pharmacotherapy:

Preconception planning for future pregnancies:

Psychotherapy continuation:

Lifestyle and supportive measures:

Contraception counseling:

Family planning and genetic counseling:

Public health and structural supports:

Follow-Up, Monitoring, and Counseling Cadence

— Initial contact within 3 weeks postpartum (in-person or virtual)

— Comprehensive postpartum visit by 12 weeks

— For patients with PMAD, intensify: visits at 2, 4, 6, and 12 weeks postpartum

— Pregnancy: at intake and in third trimester

— Postpartum: at hospital discharge or first OB contact, 4–6 week visit, and at well-child visits (1, 2, 4, 6, 9, 12 months per AAP)

— Annual mental health screening continues in primary care

— Week 1–2: tolerability, side effects, suicidality (especially adolescents and young adults)

— Week 4: response assessment, titrate if partial response

— Week 6–8: confirm remission target; if not, augment or switch

— Then every 1–3 months once stable

— Lithium: levels every 3 months when stable, plus TSH, BUN/Cr, calcium; check level 24h postpartum

— Lamotrigine: monitor for rash, increase dose during pregnancy as levels fall, reduce postpartum

— Confirm attendance at therapy referrals; many patients drop off without active care coordination

— Telehealth options improve access for new parents

— Sertraline, escitalopram, paroxetine: routine well-child visits; specific monitoring usually unnecessary

— Lithium: infant levels, TSH, BUN/Cr at intervals

— Benzodiazepines: monitor for sedation, feeding

— Sleep hygiene strategies that don't sacrifice safety

— Realistic expectations of parenting, normalize seeking help

— Safety planning, lethal means counseling (especially firearms)

— Substance use, IPV reassessment at each visit

— Contraception, return to work, breastfeeding plans

Step 3 management: After starting sertraline at the 6-week postpartum visit for moderate PPD, schedule follow-up at 2 weeks to assess tolerability/safety, again at 4 weeks for response, and confirm therapy engagement — do not wait until a routine 3-month check.

Standard postpartum follow-up framework (ACOG "fourth trimester"):

Screening cadence:

Pharmacotherapy monitoring:

Therapy follow-through:

Infant monitoring when on medications during lactation:

Counseling content:

Ethical, Legal, and Patient Safety Considerations

— Document discussion of risks of untreated illness vs. medication risks for pregnancy and lactation

— Use accessible language; provide written materials and reputable resources (LactMed, MotherToBaby)

— Capacity assessment in acute psychosis: patient may lack capacity for medication or discharge decisions

— State-specific laws govern adolescent consent for mental health treatment, contraception, and substance use treatment — know your jurisdiction

— Pregnancy itself may emancipate a minor for medical decisions in some states

— Suspected child abuse or neglect — required reporting to CPS in all states

— IPV reporting laws vary; most states do not mandate reporting of competent adult IPV without weapon use

— Distinguish reporting from referral — offer resources regardless of reporting threshold

— Mental illness alone is not grounds for removing custody; active danger, neglect, or inability to care for the infant is the threshold

— Document carefully; advocate for treatment-first approaches when safe

— Leading method in maternal suicide

— Counsel removal or secure storage during the perinatal period — frame as time-limited safety measure

— High-risk windows: hospital discharge, ED discharge, transition from OB to primary care

— Ensure follow-up scheduled, contact info exchanged, communication between OB, psychiatry, primary care, and pediatrics

— Black and Indigenous birthing patients have higher PMAD rates and lower treatment rates

— Address bias in screening (less likely to be screened, more likely to have positive screens ignored)

— CPS reporting disparities — engage cautiously and equitably

— Encourage enrollment in pregnancy exposure registries (e.g., National Pregnancy Registry for Psychiatric Medications) to improve future evidence

Board pearl: A postpartum patient with depression and intrusive (ego-dystonic) thoughts of harming her infant — this is OCD-spectrum, not infanticidal intent; she does not warrant a CPS report based on the thought alone. Diagnose, treat, follow up closely, and document the distinction.

Informed consent and shared decision-making:

Confidentiality and minors:

Mandatory reporting:

Custody and care concerns:

Firearm safety:

Transition-of-care safety:

Equity and disparities:

Research and exposure registries:

High-Yield Associations and Rapid-Fire Facts

Board pearl: When a question stem mentions a postpartum patient with rapid-onset psychosis, ask yourself: bipolar history? sleep loss? prior postpartum psychosis? — these flag the diagnosis and the need for lithium prophylaxis in subsequent pregnancies.

1 in 5 perinatal patients experiences a PMAD; leading cause of pregnancy-related mortality includes suicide and overdose.

EPDS ≥10 = positive screen; item 10 screens self-harm and must be reviewed every time.

Postpartum blues: peaks day 5, resolves by day 14, no impairment.

Postpartum depression: peripartum-onset specifier covers pregnancy through 4 weeks (clinically through 12 months).

Postpartum psychosis: onset days 1–14, psychiatric emergency, strongly tied to bipolar I; recurrence ~50% without prophylaxis.

First-line SSRI in lactation: sertraline (minimal milk transfer).

Paroxetine: avoid in pregnancy (first-trimester cardiac defects); acceptable in lactation.

Valproate, carbamazepine: avoid in pregnancy (NTDs, malformations, cognitive impairment).

Lithium: small Ebstein anomaly risk; fetal echo at 18–20 weeks; recheck level 24h postpartum due to volume shifts.

Lamotrigine: preferred bipolar maintenance in pregnancy; levels fall during pregnancy, rise postpartum — adjust accordingly.

Brexanolone (IV) and zuranolone (oral): neurosteroid GABA-A modulators specifically approved for PPD.

ECT: safe in pregnancy and postpartum; rapid response in severe, psychotic, or refractory illness.

Untreated antenatal depression: preterm birth, low birth weight, impaired bonding, childhood developmental effects.

Postpartum thyroiditis: 5–10%; biphasic; check TSH in atypical mood/anxiety.

Anti-NMDA encephalitis: psychiatric features + autonomic/seizures/dyskinesias → look for ovarian teratoma.

OCD intrusions = ego-dystonic, distressing, no intent → SSRI + CBT.

Psychotic infanticidal thoughts = ego-syntonic, delusional → hospitalize.

Suicide: firearms are the leading method in maternal suicide; counsel lethal means restriction.

Paternal/partner postpartum depression: ~10%; screen partners.

USPSTF: recommends screening for depression and anxiety in pregnant and postpartum persons; CBT/IPT for those at high risk even before symptoms emerge.

Board Question Stem Patterns

Step 3 management: When the stem describes both safety risk and uncertainty, the right answer is almost always same-day psychiatric evaluation and safety planning before any outpatient pharmacologic step.

"32-year-old at 5 days postpartum with tearfulness, mood lability, but caring for infant" → postpartum blues; reassurance, follow-up, screen again at 2 and 6 weeks. Not SSRI.

"Postpartum patient at 6 weeks with 3 weeks of anhedonia, guilt, EPDS 18, no SI, breastfeeding" → PPD; sertraline + refer for CBT/IPT, follow up in 2 weeks. Do not advise weaning.

"Postpartum day 8, rapid onset, paranoid that nurses are poisoning the baby, not sleeping, agitated" → postpartum psychosis; hospitalize, psychiatry consult, antipsychotic + mood stabilizer, consider ECT; assess underlying bipolar I.

"Postpartum patient with intrusive, ego-dystonic thoughts of dropping the baby, distressed, avoids holding baby" → perinatal OCD; SSRI + CBT; no CPS report based on thought alone.

"3 months postpartum with anxiety, tremor, palpitations, weight loss" → check TSH first (postpartum thyroiditis hyper phase) before labeling anxiety disorder.

"Pregnant patient on valproate for bipolar disorder presents for preconception counseling" → switch to lamotrigine or lithium, folic acid; do not abruptly stop mood stabilizer.

"Pregnant patient stable on sertraline asks if she should stop in third trimester due to fear of neonatal effects" → continue; risk of discontinuation/relapse outweighs transient neonatal adaptation syndrome.

"Patient with prior postpartum psychosis planning pregnancy" → preconception psychiatry, lithium prophylaxis immediately postpartum, sleep protection.

"Postpartum patient with new psychosis, autonomic instability, dyskinesias, and seizure" → think anti-NMDA receptor encephalitis; image and look for ovarian teratoma.

"Postpartum patient on citalopram, furosemide, tramadol presents confused with Na 124" → SIADH/hyponatremia + serotonin syndrome risk; hold offending agents, switch to safer regimen.

"Adolescent at 32 weeks gestation with new depression, no SI" → therapy + sertraline with close (weekly) monitoring; address IPV, school, social work.

"Postpartum patient who lost infant at 36 weeks gestation 2 weeks ago, tearful but engaged, sleeping intermittently" → normal grief; bereavement support, follow-up at 2 and 6 weeks; reassess for MDD.

One-Line Recap

Perinatal mood and anxiety disorders are common, screenable, and treatable — universal screening with EPDS/PHQ-9 across pregnancy and the first postpartum year, immediate distinction of safety risk and bipolar/psychosis features, sertraline-first SSRI therapy combined with CBT/IPT, and structured close follow-up convert preventable maternal morbidity and mortality into recovery and intact maternal-infant bonding.

Board pearl: If you remember only three things — screen everyone, separate psychosis from OCD from depression by the nature of the thought and onset tempo, and sertraline + therapy + close follow-up handles the majority of Step 3 PMAD vignettes correctly.

Screen universally: at pregnancy intake, third trimester, postpartum (4–6 weeks), and well-child visits through 12 months — EPDS ≥10 is positive; always review item 10 (self-harm).

Stratify by safety: rule in postpartum psychosis (rapid-onset psychiatric emergency, often bipolar I, admit + antipsychotic/lithium ± ECT) and distinguish ego-dystonic OCD intrusions from psychotic infanticidal ideation before deciding on outpatient vs. inpatient care.

Treat with confidence: sertraline is first-line in lactation; paroxetine avoided in pregnancy; valproate/carbamazepine avoided preconception; lamotrigine and lithium preferred for bipolar; brexanolone/zuranolone for moderate-severe PPD; ECT safe and effective for severe disease. Continue antidepressants 6–12 months after remission and across future pregnancies in recurrent illness.

Prevent and protect: address thyroid, anemia, sleep, IPV, firearms, and substance use; engage partners and pediatric care; plan lithium prophylaxis immediately postpartum for prior postpartum psychosis; follow up at 2-week intervals after initiating treatment, and remember that untreated maternal depression is itself a fetal and infant exposure with measurable harms — treatment is the safer choice.